SI3527263T1 - Derivati bipirazola kot zaviralci JAK - Google Patents
Derivati bipirazola kot zaviralci JAKInfo
- Publication number
- SI3527263T1 SI3527263T1 SI201431754T SI201431754T SI3527263T1 SI 3527263 T1 SI3527263 T1 SI 3527263T1 SI 201431754 T SI201431754 T SI 201431754T SI 201431754 T SI201431754 T SI 201431754T SI 3527263 T1 SI3527263 T1 SI 3527263T1
- Authority
- SI
- Slovenia
- Prior art keywords
- jak inhibitors
- bipyrazole derivatives
- bipyrazole
- derivatives
- jak
- Prior art date
Links
- YGAILVDTGIMZAB-UHFFFAOYSA-N 3-pyrazol-3-ylidenepyrazole Chemical class N1=NC=CC1=C1N=NC=C1 YGAILVDTGIMZAB-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824683P | 2013-05-17 | 2013-05-17 | |
| EP18215671.1A EP3527263B1 (en) | 2013-05-17 | 2014-05-16 | Bipyrazole derivatives as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3527263T1 true SI3527263T1 (sl) | 2021-05-31 |
Family
ID=50983151
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201431754T SI3527263T1 (sl) | 2013-05-17 | 2014-05-16 | Derivati bipirazola kot zaviralci JAK |
| SI201432117T SI4275756T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolni derivati kot zaviralci jak |
| SI201432046T SI3786162T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolni derivati kot zaviralci JAK |
| SI201431118T SI3231801T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolna sol kot inhibitor JAK |
| SI201430239A SI2997023T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolni derivati kot inhibitorji JAK |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201432117T SI4275756T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolni derivati kot zaviralci jak |
| SI201432046T SI3786162T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolni derivati kot zaviralci JAK |
| SI201431118T SI3231801T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolna sol kot inhibitor JAK |
| SI201430239A SI2997023T1 (sl) | 2013-05-17 | 2014-05-16 | Bipirazolni derivati kot inhibitorji JAK |
Country Status (36)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55634B1 (sr) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
| HUE043732T2 (hu) | 2007-06-13 | 2019-09-30 | Incyte Holdings Corp | Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása |
| KR20120030447A (ko) | 2009-05-22 | 2012-03-28 | ìžì¬ìŽíž ìœí¬ë ìŽì | ïœïœ ì íŽë¬Œì§ë¡ì ïŒ-ïŒ-ïŒïŒïœ-íŒë¡€ë¡ïŒ»ïŒ,ïŒ-ïœïŒœíŒëŠ¬ë¯žë-ïŒ-ìŒïŒ-ïŒïœ-íŒëŒì¡ž-ïŒ-ìŒïŒœì¥í- ëë íµí-ëížëŠŽ |
| EP2432555B1 (en) | 2009-05-22 | 2014-04-30 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| MX2011013816A (es) | 2009-06-29 | 2012-04-11 | Incyte Corp | Pirimidinonas como inhibidores de pi3k. |
| WO2011028685A1 (en) | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TWI531572B (zh) | 2010-03-10 | 2016-05-01 | è±å¡ç¹å ¬åž | äœçºïœïœïœïŒæå¶åä¹åå¶ïŒïŒïŒåºäžäºç²äºèºè¡çç© |
| US20110288107A1 (en) | 2010-05-21 | 2011-11-24 | Bhavnish Parikh | Topical formulation for a jak inhibitor |
| PH12013501001A1 (en) | 2010-11-19 | 2019-09-02 | Incyte Holdings Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| AU2012273164B2 (en) | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | äœçºïœïœïœæå¶åä¹ç°å·±åºæ°®éç°äžç·è¡çç© |
| KR20230038593A (ko) | 2011-09-02 | 2023-03-20 | ìžì¬ìŽíž íë©ì€ ìœí¬ë ìŽì | ïœïŒïœ ìµì ì ë¡ì í€í ë¡ìíŽëŠŽì믌 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | ÐÐœÑÐ°Ð¹Ñ Ð¥ÐŸÐ»ÐŽÑÐœÐ³Ñ ÐПÑпПÑейÑÐœ | СпПÑПбО Ñ Ð¿ÑПЌÑÐ¶ÐœÑ ÑпПлÑкО ÐŽÐ»Ñ ÐŸÑÑÐžÐŒÐ°ÐœÐœÑ ÑМгÑбÑÑПÑÑв jak |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | åç²ïœïœïœæå¶åä¹åå¶åºç°äžåºå代ä¹å¡å¯å¹¶å¡å¶åå¡å¯å¹¶å§å¶è¡çç© |
| NZ707495A (en) | 2012-11-01 | 2019-01-25 | Incyte Holdings Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÃN DE RUXOLITINIB DE LIBERACIÃN SOTENIDA (Divisional 2015-265) |
| SMT202100694T1 (it) | 2013-03-06 | 2022-03-21 | Incyte Holdings Corp | Procedimenti e intermedi per produrre un inibitore di jak |
| RS67392B1 (sr) | 2013-05-17 | 2025-11-28 | Incyte Holdings Corp | Derivati bipirazola kao inhibitori jak |
| CA2920108C (en) | 2013-08-07 | 2022-07-05 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| SG11201607083VA (en) * | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| PL3129021T3 (pl) | 2014-04-08 | 2021-05-31 | Incyte Corporation | Leczenie nowotworów zÅoÅliwych z komórek b za pomocÄ skojarzenia inhibitora jak i pi3k |
| CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) * | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
| AU2016222556B2 (en) | 2015-02-27 | 2020-08-27 | Incyte Holdings Corporation | Salts of Pl3K inhibitor and processes for their preparation |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| LT3371190T (lt) | 2015-11-06 | 2022-08-10 | Incyte Corporation | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai |
| EP3792256B1 (en) | 2016-01-05 | 2024-10-23 | Incyte Corporation | Pyridine compounds as pi3k-gamma inhibitors |
| TW201803871A (zh) | 2016-06-24 | 2018-02-01 | è±å¡ç¹å ¬åž | äœçºïŒ°ïŒ©ïŒïŒ«-γæå¶åä¹éç°ååç© |
| CN107759623B (zh) * | 2016-08-23 | 2020-08-14 | èå·æºå±±æºæ°Žçç©å»è¯æéå ¬åž | Jakæå¶åçäžéŽäœåå ¶å¶å€æ¹æ³ |
| KR20190045302A (ko) * | 2016-09-06 | 2019-05-02 | ìí. ížíë§-ëŒ ë¡ì ìê² | 8-(ìì í°ë-1-ìŒ)-[1,2,4]ížëŒìŽìì¡žë¡[1,5-a]íŒëŠ¬ëìŒ íí©ë¬Œ ë° ìŽì ì¡°ì±ë¬Œ ë° ì¬ì© ë°©ë² |
| MX2020003862A (es) | 2017-10-18 | 2020-08-13 | Incyte Corp | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | çŸåè±å¡ç¹å ¬åž | çšæŒæ²»ç骚é«å¢çæ§èŽ ç€çäœåéçµåçæ³ |
| EP3746429B1 (en) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| CN119386019A (zh) * | 2018-02-16 | 2025-02-07 | å èµç¹å ¬åž | çšäºæ²»çç»èå åçžå ³çç ççjak1éè·¯æå¶å |
| MX2020010322A (es) | 2018-03-30 | 2022-11-30 | Incyte Corp | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). |
| MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
| KR20210018218A (ko) | 2018-04-13 | 2021-02-17 | ìžì¬ìŽíž ìœí¬ë ìŽì | ìŽìížëì죌ì§íì© ë°ìŽì€ë§ì»€ |
| CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | åäº¬å€§åŠ | è³åºæ°®æç¯äžç·ç±»ååç©çå¶å€æ¹æ³ |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3âquinasa (pi3k) (divisional 2021-0165) |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| TWI884142B (zh) | 2018-12-19 | 2025-05-21 | çŸåè±å¡ç¹å ¬åž | çšæŒæ²»çèè žéçŸç ä¹jak1è·¯åŸæå¶å |
| MA55201A (fr) | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| TW202102222A (zh) * | 2019-03-19 | 2021-01-16 | çŸåè±å¡ç¹å ¬åž | çœæç ä¹çç©æšèšç© |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧æ©ç§æ¯æ¬§å ¬åž | çšäºæ²»ççççDbaitååäžæ¿é ¶æå¶åçç»å |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ãã£ã¹ã¯ã»ã¡ãã£ã·ã³ã»ã€ã³ã³ãŒãã¬ã€ããã | 骚é«ç·ç¶çããã³é¢é£ç¶æ ãåŠçœ®ããããã®æ¹æ³ |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021270458A1 (en) | 2020-05-13 | 2022-11-10 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis |
| TWI897972B (zh) | 2020-06-02 | 2025-09-21 | çŸåè±å¡ç¹å ¬åž | 補åïœïœïœïŒæå¶åä¹æ¹æ³ |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4200300A1 (en) | 2020-08-18 | 2023-06-28 | Incyte Corporation | Process and intermediates for preparing a jak inhibitor |
| IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK1 inhibitor |
| CN112159394B (zh) * | 2020-10-09 | 2021-10-22 | åå Žç¹ç§çœçç©ç§ææéå ¬åž | äžç§äœäžºjakæ¿é ¶æå¶åçå°ååååç©åå ¶çšé |
| JP2023552424A (ja) | 2020-12-04 | 2023-12-15 | ã€ã³ãµã€ãã»ã³ãŒãã¬ã€ã·ã§ã³ | ç®èçŸæ£ã®æ²»çã®ããã®ãã¿ãã³ïœé¡äŒŒäœãæããïœïœïœé»å®³å€ |
| EP4259131A1 (en) * | 2020-12-08 | 2023-10-18 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| CN114081889A (zh) * | 2020-12-29 | 2022-02-25 | äžæµ·å²žéå»è¯ç§ææéå ¬åž | é¢é²ææ²»çegfråèœåŒåžžçžå ³çå¯äœçšçæ¹æ³ |
| WO2022150676A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| HRP20251436T1 (hr) | 2021-05-03 | 2025-12-19 | Incyte Corporation | Inhibitori jak1 puta za lijeÄenje prurigo nodularis |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| KR20250044437A (ko) | 2022-08-05 | 2025-03-31 | ìžì¬ìŽíž ìœí¬ë ìŽì | Jak ìµì ì 륌 ì¬ì©í ëëë¬êž°ì ì¹ë£ |
| KR20250174908A (ko) | 2023-03-16 | 2025-12-15 | ìžì¬ìŽíž ìœí¬ë ìŽì | ì²ìì ì¹ë£ë¥Œ ìí jak1 ê²œë¡ ì íŽì |
| CN117186078A (zh) * | 2023-11-06 | 2023-12-08 | è¯åº·äŒæ(å京)å»è¯ç§ææéå ¬åž | æ°ä»£æ°®æç¯äžç·ç±»jakæå¶åè¯ç©åçšé |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60106847U (ja) | 1983-12-27 | 1985-07-20 | å¯å£«éå·¥æ¥æ ªåŒäŒç€Ÿ | 宀å€åŸåé¡ |
| JP2650681B2 (ja) | 1987-07-10 | 1997-09-03 | æ ªåŒäŒç€Ÿããªãã¹ãã³ | 空æ°ã°ã |
| JPH0515775Y2 (enExample) | 1987-07-13 | 1993-04-26 | ||
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| CZ303572B6 (cs) | 2000-06-28 | 2012-12-12 | Smithkline Beecham P. L. C. | Jemne rozmelnenÃœ prostredek a zpusob jeho prÃpravy |
| MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
| MXPA04004137A (es) | 2001-10-30 | 2005-01-25 | Novartis Ag | Derivados de estauroesporina como inhibidores de la actividad de cinasa de tirosina del receptor flt3. |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| RS55634B1 (sr) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
| HUE043732T2 (hu) | 2007-06-13 | 2019-09-30 | Incyte Holdings Corp | Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| CN101910152B (zh) * | 2007-11-16 | 2014-08-06 | å å¡ç¹å ¬åž | äœäžºjanusæ¿é ¶æå¶åç4-å¡ååº-n-è³åºå§å¶-2-èºå4-å¡ååº-n-æè³åºå§å¶-2-èº |
| EA017218B1 (ru) * | 2008-03-11 | 2012-10-30 | ÐÐœÑÐ°Ð¹Ñ ÐПÑпПÑейÑÐœ | ÐÑПОзвПЎМÑе азеÑОЎОМа О ÑОклПбÑÑаМа как ОМгОбОÑПÑÑ jak-кОМаз |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طر٠ÙاصÙØ§Ø Ù Ø«ØšØ·Ø§Øª اÙزÙÙ jak ٠اÙ٠رÙؚات اÙÙسÙطة اÙ٠تعÙÙØ© ØšÙ |
| KR20120030447A (ko) | 2009-05-22 | 2012-03-28 | ìžì¬ìŽíž ìœí¬ë ìŽì | ïœïœ ì íŽë¬Œì§ë¡ì ïŒ-ïŒ-ïŒïŒïœ-íŒë¡€ë¡ïŒ»ïŒ,ïŒ-ïœïŒœíŒëŠ¬ë¯žë-ïŒ-ìŒïŒ-ïŒïœ-íŒëŒì¡ž-ïŒ-ìŒïŒœì¥í- ëë íµí-ëížëŠŽ |
| EP2432555B1 (en) * | 2009-05-22 | 2014-04-30 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011028685A1 (en) * | 2009-09-01 | 2011-03-10 | Incyte Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| KR101805936B1 (ko) | 2009-10-09 | 2017-12-07 | ìžì¬ìŽíž íë©ì€ ìœí¬ë ìŽì | 3-ïŒ4-ïŒ7-íŒë¡€ë¡ã2,3-ïœãíŒëŠ¬ë¯žë-4-ìŒïŒ-1-íŒëŒì¡ž-1-ìŒïŒ-3-ì¬ìŽíŽë¡íížíë¡íëížëŠŽì íìŽëë¡ì€, ìŒí ë° êžë£šì¿ ë¡ëìŽë ì ë첎 |
| MX2012009541A (es) | 2010-02-18 | 2012-10-01 | Incyte Corp | Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa. |
| TWI531572B (zh) | 2010-03-10 | 2016-05-01 | è±å¡ç¹å ¬åž | äœçºïœïœïœïŒæå¶åä¹åå¶ïŒïŒïŒåºäžäºç²äºèºè¡çç© |
| MX2012011941A (es) * | 2010-04-14 | 2013-08-27 | Array Biopharma Inc | Imidazo [1, 2-c] pirimidinas 5, 7-substituidas como inhibidores de jak cinasas. |
| US20110288107A1 (en) | 2010-05-21 | 2011-11-24 | Bhavnish Parikh | Topical formulation for a jak inhibitor |
| PH12013501001A1 (en) * | 2010-11-19 | 2019-09-02 | Incyte Holdings Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| US9926601B2 (en) | 2011-02-24 | 2018-03-27 | Massachusetts Institute Of Technology | Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer |
| AU2012273164B2 (en) * | 2011-06-20 | 2015-05-28 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | äœçºïœïœïœæå¶åä¹ç°å·±åºæ°®éç°äžç·è¡çç© |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | ÐÐœÑÐ°Ð¹Ñ Ð¥ÐŸÐ»ÐŽÑÐœÐ³Ñ ÐПÑпПÑейÑÐœ | СпПÑПбО Ñ Ð¿ÑПЌÑÐ¶ÐœÑ ÑпПлÑкО ÐŽÐ»Ñ ÐŸÑÑÐžÐŒÐ°ÐœÐœÑ ÑМгÑбÑÑПÑÑв jak |
| AU2012312303B2 (en) | 2011-09-22 | 2016-09-15 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| TW201406761A (zh) * | 2012-05-18 | 2014-02-16 | Incyte Corp | åç²ïœïœïœæå¶åä¹åå¶åºç°äžåºå代ä¹å¡å¯å¹¶å¡å¶åå¡å¯å¹¶å§å¶è¡çç© |
| NZ707495A (en) | 2012-11-01 | 2019-01-25 | Incyte Holdings Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÃN DE RUXOLITINIB DE LIBERACIÃN SOTENIDA (Divisional 2015-265) |
| SMT202100694T1 (it) | 2013-03-06 | 2022-03-21 | Incyte Holdings Corp | Procedimenti e intermedi per produrre un inibitore di jak |
| RS67392B1 (sr) | 2013-05-17 | 2025-11-28 | Incyte Holdings Corp | Derivati bipirazola kao inhibitori jak |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | ٠؎تÙات سÙÙا٠ÙÙÙ ØšÙرÙÙا٠Ùد Ùاستخدا٠Ùا ÙادÙÙØ© Ù٠عاÙجة اÙتÙاؚ اÙÙؚد ÙÙع ØšÙ |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CA2920108C (en) | 2013-08-07 | 2022-07-05 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| SG11201607083VA (en) | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CR20170260A (es) | 2014-12-16 | 2017-08-21 | Novartis Ag | COMPUESTOS DE ISOXAZOL DE ÃCIDO HIDROXÃMICO COMO INHIBIDORES DE LpxC |
| CN119386019A (zh) | 2018-02-16 | 2025-02-07 | å èµç¹å ¬åž | çšäºæ²»çç»èå åçžå ³çç ççjak1éè·¯æå¶å |
| TWI897972B (zh) | 2020-06-02 | 2025-09-21 | çŸåè±å¡ç¹å ¬åž | 補åïœïœïœïŒæå¶åä¹æ¹æ³ |
| JP2023552424A (ja) | 2020-12-04 | 2023-12-15 | ã€ã³ãµã€ãã»ã³ãŒãã¬ã€ã·ã§ã³ | ç®èçŸæ£ã®æ²»çã®ããã®ãã¿ãã³ïœé¡äŒŒäœãæããïœïœïœé»å®³å€ |
| EP4259131A1 (en) | 2020-12-08 | 2023-10-18 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
-
2014
- 2014-05-16 RS RS20251023A patent/RS67392B1/sr unknown
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 SM SM20250397T patent/SMT202500397T1/it unknown
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 SI SI201432117T patent/SI4275756T1/sl unknown
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 ES ES23185889T patent/ES3047826T3/es active Active
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
- 2014-05-16 TW TW110101630A patent/TWI840646B/zh active
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 SM SM20170258T patent/SMT201700258T1/it unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 MX MX2020004506A patent/MX385187B/es unknown
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 KR KR1020227030853A patent/KR102663357B1/ko active Active
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active Active
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/en active
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 FI FIEP23185889.5T patent/FI4275756T3/fi active
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 TW TW112149597A patent/TWI885650B/zh active
- 2014-05-16 KR KR1020247014111A patent/KR102729910B1/ko active Active
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 LT LTEP23185889.5T patent/LT4275756T/lt unknown
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 MX MX2015015738A patent/MX373238B/es active IP Right Grant
- 2014-05-16 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 EP EP23185889.5A patent/EP4275756B1/en active Active
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 PT PT231858895T patent/PT4275756T/pt unknown
- 2014-05-16 PL PL20201593.9T patent/PL3786162T3/pl unknown
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
- 2014-05-16 SM SM20230352T patent/SMT202300352T1/it unknown
- 2014-05-16 DK DK23185889.5T patent/DK4275756T3/da active
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 SM SM20190223T patent/SMT201900223T1/it unknown
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active Active
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 EP EP25180368.0A patent/EP4620528A3/en active Pending
- 2014-05-16 SM SM20210040T patent/SMT202100040T1/it unknown
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 HR HRP20251220TT patent/HRP20251220T1/hr unknown
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en not_active Ceased
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
-
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563B1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
-
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
-
2017
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
-
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/en unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
-
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
-
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
-
2021
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
-
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
-
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
-
2024
- 2024-01-02 US US18/402,493 patent/US12247020B2/en active Active
- 2024-05-15 JP JP2024079435A patent/JP2024105557A/ja active Pending
-
2025
- 2025-02-05 US US19/045,868 patent/US20250206726A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL242453B (en) | Bipyrazole derivatives as jak inhibitors | |
| IL240863A0 (en) | Amatoxin derivatives | |
| LT2953944T (lt) | Piridazinono amidų dariniai | |
| ZA201506156B (en) | Novel inhibitors | |
| SG11201600743WA (en) | Oxoquinazolinyl-butanamide derivatives | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| LT3087076T (lt) | Imidazopirazinono dariniai |